News - Appointments

The UK biotech OMass Therapeutics Ltd has appointed Rosamond Deegan as its chief executive officer to manage its high-resolution mass spectrometry platform for drug discovery.

Novigenix SA has named Jan Groen as chief executive to help lead the company’s commercialisation of products for early cancer detection. The Swiss company’s technology involves identifying disease specific mRNA signatures in circulating immune cells.

Harald Hampel, an expert in neurodegenerative diseases, has been appointed head of global medical affairs at Eisai Inc to oversee the company’s Alzheimer’s disease and dementia research.

Mohammed Dar, formerly of AstraZeneca Plc, has joined the UK biotech Immunocore Ltd as chief medical officer and head of clinical development to manage the company’s portfolio of T cell receptor therapies.

Christian Meisel has joined the German diagnostics company Molecular Health GmbH as chief medical officer to oversee development of the company’s tools for precision medicine.

James Summers, a neuroscience expert, has joined the board of Mission Therapeutics Ltd as an independent member to help the UK company develop its small molecule drugs for neurodegenerative disorders, mitochondrial diseases and fibrosis.

Amy Pott, a pharma executive with experience in public healthcare, has joined Swedish Orphan Biovitrum AB (Sobi) to lead its North American operations with a focus on commercialising medicines for rare diseases.

The Swedish biotech Medivir AB has appointed Magnus Christensen as its new chief financial officer, effective 12 August.